Literature DB >> 22035550

Pioglitazone and bladder cancer.

Dominique Hillaire-Buys, Jean-Luc Faillie, Jean-Louis Montastruc.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22035550     DOI： 10.1016/S0140-6736(11)61662-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  19 in total

1.  Stay vigilant: a glitazone (pioglitazone) can hide a glitazar!

Authors:  Dominique Hillaire-Buys; Jean-Luc Faillie; Jean-Louis Montastruc; Pierre Petit
Journal:  Eur J Clin Pharmacol       Date:  2012-05-11       Impact factor: 2.953

Review 2.  A molecular rheostat at the interface of cancer and diabetes.

Authors:  Mahasin A Osman; Fazlul H Sarkar; Enrique Rodriguez-Boulan
Journal:  Biochim Biophys Acta       Date:  2013-04-29

3.  Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.

Authors:  Isabelle N Colmers; Samantha L Bowker; Sumit R Majumdar; Jeffrey A Johnson
Journal:  CMAJ       Date:  2012-07-03       Impact factor: 8.262

4.  Understanding drug preferences, different perspectives.

Authors:  Peter G M Mol; Arna H Arnardottir; Sabine M J Straus; Pieter A de Graeff; Flora M Haaijer-Ruskamp; Elise H Quik; Paul F M Krabbe; Petra Denig
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

5.  Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis.

Authors:  Richard M Turner; Chun S Kwok; Chen Chen-Turner; Chinedu A Maduakor; Sonal Singh; Yoon K Loke
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

Review 6.  Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?

Authors:  Jean-Luc Faillie; Pierre Petit; Jean-Louis Montastruc; Dominique Hillaire-Buys
Journal:  Drug Saf       Date:  2013-09       Impact factor: 5.606

Review 7.  Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.

Authors:  Raymond E Soccio; Eric R Chen; Mitchell A Lazar
Journal:  Cell Metab       Date:  2014-09-18       Impact factor: 27.287

8.  Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.

Authors:  Julio Rosenstock; Marisa Vico; Li Wei; Afshin Salsali; James F List
Journal:  Diabetes Care       Date:  2012-03-23       Impact factor: 19.112

9.  Diabetes mellitus: Exploring the challenges in the drug development process.

Authors:  Julius A Vaz; Ashis Patnaik
Journal:  Perspect Clin Res       Date:  2012-07

Review 10.  Drug safety assessment in clinical trials: methodological challenges and opportunities.

Authors:  Sonal Singh; Yoon K Loke
Journal:  Trials       Date:  2012-08-20       Impact factor: 2.279
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.